Hydreight Technologies (NURS) investor relations material

Executive summary

• Achieved strong Q2 results and 33% year-over-year revenue growth for H1 2025, with three consecutive quarters of profitability and validation of growth in all three healthcare verticals.

• Exceeded internal metrics across all business verticals, expanded offerings to include genetic testing, anti-aging, and mental wellness, and advanced onboarding of franchise and direct-to-consumer partners.

• Positioned as a compliance-driven, tech-enabled platform with a unique offering across all 50 states.

• Focused on trend-based growth, recurring SaaS revenue, operational scalability, and modular platform development.

Financial highlights

• Q2 2025 GAAP revenue reached $5.38M, topline revenue $7.35M, both up 31% year-over-year; cash on hand at quarter-end was $6.10M.

• First six months GAAP revenue totaled $9.92M, a 33% increase year-over-year; topline revenue was $13.88M, up 33%.

• Achieved cash flow positivity, profitability, and margin improvement, with adjusted EBITDA for Q2 2025 at $182K.

• License holders in the nurse network increased 77% year-over-year in Q2; pharmacy orders rose nearly 50%.

• Gross margin for Q2 2025 was $1.93M, up from $1.56M in Q2 2024.

Outlook and guidance

• Maintaining guidance of 1.3M orders for the year, with no evidence to change targets.

• Positioned to scale efficiently and achieve 2025 objectives through continued investment in technology, acquisitions, and strategic partnerships.

• On track to surpass pharmacy SKU order goals for June-August, with 42,829 orders in the first 60 days.

• Expecting continued order and revenue growth in Q3 and Q4, driven by onboarding and product expansion.

• Focused on trend consistency rather than one-off spikes in orders.